结直肠癌患者5-氟尿嘧啶诱导肝毒性的CT纹理分析作为潜在生物标志物的作用
本研究回顾性纳入43例接受5-FU为基础化疗的结直肠癌患者,评估CT纹理分析能否作为肝毒性生物标志物。结果显示,34例(79%)出现肝功能指标升高的患者,其基线至首次随访CT的肝脏纹理参数(均值、熵、偏度、标准差)有显著变化,而无肝功能升高者无显著变化;在56%的患者中,纹理变化早于血液肝功能指标升高出现。
要点
- 5-FU化疗后肝功能升高患者首次随访CT即可见肝脏纹理参数早期变化。
- 纹理变化可早于血液肝功能指标升高出现,提示影像可能先于实验室发现。
- 无肝功能升高患者中未观察到肝脏纹理参数显著变化。
核心结论
- 该概念验证研究表明,接受5-FU为基础化疗的结直肠癌患者中,肝功能指标升高者在首次随访CT上即出现肝脏纹理的早期变化,且超过50%的病例中这些变化早于血液肝功能指标升高。
研究设计与样本
- 经IRB批准、符合HIPAA的回顾性研究,共纳入43例(23例女性,平均年龄56岁)基线肝功能正常且具备化疗前基线和化疗期间首次随访CT(中位1.7个月,四分位距1.5-2.5)的结直肠癌患者,在基线和首次随访CT上于肝右叶和左叶各放置一个单层感兴趣区,使用商用软件TexRAD提取纹理特征(均值、熵、峰度、偏度、正像素均值、标准差)。
诊断标准与关键数值
- 纹理特征包括均值、熵、峰度、偏度、正像素均值和标准差;在肝功能升高组(n=34,79%)中,基线与首次随访CT之间的均值、熵、偏度和标准差差异有统计学意义(p值范围0.007-0.047),而峰度无显著变化;无肝功能升高组(n=9,21%)中所有纹理特征均无显著变化。
临床应用与阅片要点
- 对于接受5-FU为基础化疗的结直肠癌患者,在首次随访CT阅片时可关注肝脏纹理参数(均值、熵、偏度、标准差)的早期变化,这些变化可能早于血液肝功能指标升高出现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess if CT texture analysis (TA) can serve as a biomarker of liver toxicity in patients with colorectal cancer treated with 5-fluorouracil (5-FU)-based chemotherapy.
METHODS: In this IRB-approved, HIPAA-compliant retrospective study, patients with colorectal cancer treated with 5-FU-based regimens during 2008-2010 were identified from institutional electronic database. Total 43 patients (23 women; mean age 56 years) with normal baseline liver function tests (LFTs), availability of baseline (pre-chemotherapy) and first follow-up CT (median 1.7 months, interquartile range (IQR) 1.5-2.5) performed during chemotherapy were included. Two single-slice ROI of right and left liver lobe were obtained on baseline and first follow-up CT for TA. Texture features [mean, entropy, kurtosis, skewness, mean of positive pixel, standard deviation (SD)] were extracted using a commercially available software (TexRAD; Feedback Medical Ltd, Cambridge, UK). Changes in texture parameters between baseline and follow-up CT were evaluated with Wilcoxon signed-rank test for patients with and without LFT elevation during chemotherapy.
RESULTS: Patients with LFT elevation (n = 34; 79%) showed significantly different mean, entropy, skewness, and SD (p values range 0.007-0.047) between baseline and first follow-up CT. No significant changes in features were observed in patients without LFT elevation (n = 9; 21%). In 19 patients (56%), first follow-up CT was performed before elevation of LFTs was observed.
CONCLUSIONS: This proof-of-concept study shows that there are early changes in liver texture on first follow-up CT in patients with LFT elevation during 5-FU-based chemotherapy for colorectal cancer. In more than 50% of cases, these changes occur before LFT elevation becomes evident on blood tests.
引用
- Alessandrino F, Qin L, Cruz G, et al. 5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. Abdom Radiol (NY). 2019. PMID: 31250179. doi:10.1007/s00261-019-02110-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。